Research Article

Qingxin K'aiqiao Fang Inhibits $A\beta_{25-35}$-Induced Apoptosis in Primary Cultured Rat Hippocampal Neuronal Cells via the p38 MAPK Pathway: An Experimental Validation and Network Pharmacology Study

Tian-Qi Wang,1,2 Xiao-Xiao Lai,1,2 Lu-Ting Xu,1,2 Yan Shen,1,2 Jian-Wei Lin,1,2 Shi-Yu Gao,1,2 and Hai-Yan Hu

1The Second Affiliated Hospital and Yuying Children’s Hospital of Wenzhou Medical University, 109 Xue Yuan Xi Road, Lu Cheng District, Wenzhou 325000, China
2The Second Clinical College, Wenzhou Medical University, Wenzhou 325003, China

Correspondence should be addressed to Hai-Yan Hu; wzykdxzyk@163.com

Received 5 April 2020; Revised 7 July 2020; Accepted 13 July 2020; Published 4 August 2020

Copyright © 2020 Tian-Qi Wang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Qingxin kaiqiao fang (QKF), a traditional Chinese medicine compound, has been applied to treat Alzheimer’s disease (AD) for many years and has exhibited remarkable effects. However, the underlying mechanism is still not explicit. The current study aims to investigate whether QKF exerts an antiapoptotic role through the p38 MAPK pathway in the course of AD. Network pharmacology analysis was applied to study the effective components, possible therapeutic targets, and AD-related pathway of QKF. Further, the AD cell model was established using amyloid-beta ($A\beta$) 25-35 peptide and primary hippocampal neuronal cells extracted from newborn Sprague-Dawley rats. Microtubule-associated protein-2 (MAP-2) imaging was used to detect the morphology of hippocampal neurons. Western blot (WB) analysis was applied to detect the protein expression levels of p38 MAPK, p-p38 MAPK, Bcl-2, Bax, caspase-3, and cleaved caspase-3. Cell viability and apoptosis were determined using cell counting kit-8 (CCK-8) and terminal deoxynucleotidyl transferase-mediated dUTP nick end-labeling (TUNEL) assays, respectively. SB203580 and U46619 were used to detect changes in cell morphology, cell viability, and apoptosis upon inhibiting or activating p38 MAPK. Our present work showed that QKF protects hippocampal neuronal morphology, enhances cell viability, and reduces the number of TUNEL-positive cells. In addition, our results showed that QKF increased the expression levels of antiapoptotic proteins and decreased the expression of proapoptotic proteins. QKF at 25 mg·mL$^{-1}$ best inhibited neuronal apoptosis among the three doses of QKF by suppressing p38 MAPK activity. Collectively, QKF plays an antiapoptotic role via the p38 MAPK pathway.

1. Introduction

As a serious neurodegenerative disease in aged individuals, Alzheimer’s disease (AD) is characterized by the formation of intracellular neurofibrillar tangles, extracellular deposits of senile plaques (SP), and the loss of neurons [1]. It is generally accepted that the apoptosis-induced death of a large number of neurons is a common feature in the brains of patients with AD [2]. This programmed cell death can be induced by multiple factors, one of which is the abnormal aggregation and deposition of amyloid-beta ($A\beta$) fragments, the main component of SP. Among the $A\beta$ fragments studied to date, $A\beta_{25-35}$ is the shortest, but it retains the toxicity of the full-length peptide and exhibits a significant level of molecular aggregation [3, 4]. Evidence suggests that the excessive deposition of $A\beta$ in the hippocampus leads to changes in nerve function and eventually cognitive dysfunction, as the hippocampus is one of the most delicate areas in the brain and primarily responsible for learning and memory [5]. Moreover, some studies have shown that
hippocampal neuronal damage induced by Aβ can be mediated by the regulation of p38 mitogen-activated protein kinase (p38 MAPK) [6, 7]. A member of the MAPK family, p38 MAPK, is closely related to the regulation of cell proliferation, differentiation, survival, and death. Recent studies have found that its phosphorylation is markedly increased in both the hippocampi of AD rats and in cultured neurons [8, 9]. In addition, p38 MAPK activation leads to programmed neuronal cell death primarily through alterations in the expression of proteins involved in apoptosis, including caspase-3, the antiapoptotic protein regulator Bcl2, and the proapoptotic protein regulator Bax [10]. In view of the role of p38 MAPK in apoptosis, SB203580, a direct inhibitor of p38 MAPK, and U46619, an agonist of p38 MAPK, are currently applied by many researchers to assess whether the antiapoptotic role of p38 MAPK is mediated by its suppression [11, 12]. Qingxin kaiqiao fang (QKF), which is based on Fumanjian, a notable traditional Chinese medicine compound from Jingyue Quanshu that was first described by Zhang Jingyue during the Ming Dynasty, is made mainly from Radix Rehmanniae (Sheng Di Huang), Radix Paeoniae Alba (Bai Shao), Radix Ophiopogonis (Mai dong), Cortex Moutan Radicis (Mu dan pi), Portia cocos (Fu Ling), Herba Dendrobii Rhizoma (Shi Hu), Rhizoma Acori Tatarinowii (Shi Chang Pu), Rhizoma Anemarrhenae (Zhi mu), Sophorae Flavescentis (Ku Shen), and Pericarpium Citri Reticulatae (Chenpi). A network pharmacology analysis, which integrates high-throughput data integration, database retrieval, data mining, target prediction, laboratory simulations, and other research methods [13], was applied in this study to reveal the complex mechanism of QKF in the treatment of AD.

2. Materials and Methods

2.1. Active Ingredients Screening and Targets Identification. The BATMAN-TCM database (a bioinformatics analysis tool for determining the molecular mechanism of TCM) (http://bionet.ncpsb.org/batman-tcm/) was used to search for the compounds contained in QKF. Further, we predicted the potential targets of the above drugs based on the BATMAN-TCM database and set a target score≥20 as the threshold for targets. Afterward, a “QKF-compound-target” network was constructed and analyzed using Cytoscape 3.7.2 software. AD-related targets were retrieved from the following five databases, namely, Online Mendelian Inheritance in Man (OMIM; https://www.omim.org/), PharmGKB (http://www.pharmgkb.org/), GeneCards (http://www.geneCards.org/), GAD (https://www.geneticassociationdb.nih.gov/), and KEGG (http://www.kegg.jp/) databases.

2.2. Network Establishment. The drug-related targets and disease targets were standardized by using the UniProt database. The String database (https://string-db.org/) was used to analyze protein-protein interactions (PPIs). Afterward, the network analyzer function of Cytoscape 3.7.2 software was used to analyze the network parameters. The topological analysis was used to identify the key genes for which the network degrees and betweenness were greater than the mean values.

2.3. Gene Pathway and Functional Analysis. The core target genes were identified using the DAVID database (http://david.nicrf.gov/). The signaling pathways and biological processes of QKF relevant to the treatment of AD were analyzed by gene ontology (GO) enrichment analysis (http://www.geneontology.org) and the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis (http://www.kegg.jp/) (P ≤ 0.01).

2.4. Main Reagents. Poly-L-lysine (PLL) (10x) was purchased from Beijing Solarbio Science and Technology Co., Ltd. (Beijing, China). DMEM/F12 (1:1), Neurobasal Plus Medium, B27 Plus Supplement (50x), HBSS (1x), FBS, and 0.25% trypsin were obtained from Gibco (Grand Island, New York, USA). The Aβ25-35 fragment and dimethyl sulfoxide (DMSO) were purchased from Sigma (St. Louis, MO, USA). Donepezil hydrochloride, SB203580, and U46619 were obtained from Santa Cruz Biotechnology Inc. (Delaware, USA). L-Glutamine was obtained from Thermo Fisher (Massachusetts, USA). The rabbit polyclonal antibodies against MAP2 were purchased from Proteintech Group, Inc. (Chicago, USA). Rabbit monoclonal antibodies against p38 MAPK, p-p38 MAPK, caspase-3, cleaved caspase-3, and Bax were purchased from Cell Signaling Technology (Beverly, MA, USA). The primary antibody against Bcl-2 was purchased from Abcam (Cambridge, UK). Horseradish peroxidase- (HRP-) conjugated IgG secondary antibody was purchased from Beijing Bios Biotechnology Co., Ltd. (Beijing, China), and the BCA protein assay kit was obtained from Beyotime Biotechnological Technology Co., Ltd. (Shanghai, China).

2.5. Preparation of QKF and Aβ25-35. QKF is composed of 10 herbs: Radix Rehmanniae (Sheng Di Huang), Radix Paeoniae Alba (Bai Shao), Radix Ophiopogonis (Mai dong), Cortex Moutan Radicis (Mu dan pi), Portia cocos (Fu Ling), Herba Dendrobii Rhizoma (Shi Hu), Rhizoma Acori Tatarinowii (Shi Chang Pu), Rhizoma Anemarrhenae (Zhi mu), Sophorae Flavescentis (Ku Shen), and Pericarpium Citri Reticulatae (Chenpi), all of which are recorded in the Chinese Pharmacopoeia, as being present in QKF at a ratio of 2:2:2; 2:2:2; 2:1:5; 1:5:1 on a dry-weight basis, respectively. All herbs were provided by the Second Affiliated Hospital of Wenzhou Medical University and verified by the Department of Chinese Materia Medical of Wenzhou Medical University. To make the 1 g·mL⁻¹ stock solution, the raw herbs were decocted with 10 times the volume of distilled water, extracted twice, filtered, and concentrated, and the drug stocks were then sterilized in an autoclave (Panasonic Co., Ltd. Tokyo, Japan; MLS-3751L) and stored at 4°C until use. The Aβ25-35 peptide was dissolved in DMSO at a concentration of 100 µmol L⁻¹ and then placed in a 37°C thermostat water bath three days prior to use. Prior to use, it was diluted to 10 µmol L⁻¹ with a maintenance medium.
2.6. Primary Hippocampal Neuron Cultures. One-day-old Sprague-Dawley (5-6 g) rats were purchased from Beijing Vital River Laboratory Animal Technology Co., Ltd. (certification number SCXK 2012-0001; Beijing). The rats were sterilized using 75% ethanol and then euthanized. The skin and skull were cut with a pair of sterile scissors. The brain was removed from the skull with a pair of tweezers and placed in a small Petri dish with a small amount of HBSS. The cerebral hemispheres were peeled back, and the hippocampus was removed and placed in a Petri dish with the proper amount of HBSS. After all hippocampi were isolated, they were cut into 1 mm sections with a pair of ophthalmic scissors and washed with PBS, and then 3 ml of 0.125% trypsin was added to the sections which were incubated for 15 min at 37°C. Fifteen minutes later, the same amount of DMEM/F12, containing 10% FBS and 1% penicillin-streptomycin solution, was added to terminate cell digestion, and the solution was gently triturated into a cell suspension with a sterile pipette. The cell suspension was then filtered with a 200-mesh copper sieve, and the filtered cell suspension underwent centrifugation (4°C; 500 r) for 2 min, after which the supernatant was discarded, following which fresh culture medium was added. Finally, the cells were placed in an incubator with 5% CO2 and incubated at 37°C for 1 h to induce differential adhesion. Following cell counting using a blood cell counting chamber, the cells were seeded in a 6-well plate at a density of 2 × 10^4/well. The culture medium was replaced with maintenance medium composed of Neurobasal Plus Medium, B27 Plus, L-glutamine, and penicillin-streptomycin solution four hours later. Thereafter, half of the maintenance medium was replaced with fresh medium every two days. The abovementioned animal experiments were conducted in accordance with the ethical requirements approved by the Chinese Association of Accreditation of Laboratory Animal Care.

2.7. Cell Grouping. After 7 days of culture, the neurons were randomly grouped as follows: control group; model group, which was then treated with 10 μmol·L⁻¹ Aβ25-35 alone on the 8th day of culture; 25 mg·ml⁻¹ QKF group; 12.5 mg·ml⁻¹ QKF group; 6.25 mg·ml⁻¹ QKF group; donepezil, which was used as a positive control group and treated with 10 μmol·L⁻¹ donepezil hydrochloride; 25 mg·ml⁻¹ QKF + SB203580 group, which was treated with 10 μmol·L⁻¹ SB203580 and 25 mg·ml⁻¹ QKF; and 25 mg·ml⁻¹ QKF + U46619 group, which was treated with 10 μmol·L⁻¹ U46619 and 25 mg·ml⁻¹ QKF. After 24 h of drug treatment, Aββ25-35 (at a final concentration of 10 μmol·L⁻¹) was added to all groups (except for the control group) for 24 h to establish the AD cell model. Meanwhile, the control group was incubated with the same volume of culture medium for the same length of time.

2.8. Cell Observation. Cell morphology was observed under a Nikon inverted fluorescent microscope (Nikon Corp., Tokyo, Japan) at 4 h and 1, 3, 5, and 7 days. After 9 days of culture, the neurons were washed with PBS three times (5 min each time), fixed with 4% paraformaldehyde for 20 min at room temperature, washed with PBS another three times, permeated with 0.2% Triton X-100 at room temperature, washed with PBS a further three times, blocked with 5% BSA, and finally washed with PBS three more times. The neurons were incubated with anti-SOX2 primary antibody (1:200) in a wet box at 4°C for 24 h, washed with PBS three times, incubated with anti-rabbit IgG (H + L) at 37°C for 1 h in the dark, and washed with PBS three times. The neurons were incubated with DAPI for 10 min at room temperature, treated with antifluorescence quenching and sealing tablets, and washed with PBS three times (5 min each time). Images of neurons and nuclei were captured under a high-power microscope.

2.9. Western Blot Analysis. The total protein was extracted with lysis buffer, and the total protein concentration was determined using the bicinchoninic acid assay. Proteins were separated by 10% PAGE and subsequently transferred onto polyvinylidene fluoride (PVDF) membranes (Roche Applied Science, Indianapolis, IN, USA). The membranes were blocked for 2 h in skim milk blocking buffer and washed 3 times with TBS/0.1% Tween 20 before incubation with primary antibodies (1:1000) against p38 MAPK, p-p38 MAPK, Bcl2, Bax, caspase-3, cleaved caspase-3, and β-tubulin overnight at 4°C. The membranes were then incubated with HRP-conjugated goat anti-rabbit secondary antibody as appropriate for 2 h at room temperature. After being washed three times with TBST, the immunoreactive proteins were visualized using an ECL Plus reagent kit. Finally, the density of each band was quantified using AlphaEaseFC, and β-tubulin served as the internal control.

2.10. Cell Viability Assay. Cell viability was assessed by cell counting kit-8 (CCK-8) assay (Dojindo Laboratories, Tokyo, Japan) according to the manufacturer’s instructions. In short, hippocampal neurons were plated directly in 96-well plates at a density of 1 × 10⁴ cells/well and grouped into five wells for each group. After treatment with the corresponding drugs for 24 h, the cells were exposed to Aββ25-35 (10 μmol·L⁻¹) for an additional 24 h and then cultured in maintenance medium (100 μL) and CCK-8 reagent (10 μL) for 4 h at 37°C. Finally, cell viability was determined by reading the optical density (OD) at a wavelength of 450 nm using an enzyme-labeled instrument (Infinite 200Pro, Tecan, Switzerland).

2.11. TUNEL Staining. TUNEL staining was performed with an In Situ Cell Death Detection Kit (Roche, Mannheim, Germany), according to the manufacturer’s instructions. Neurons at day 9 were washed with PBS three times (5 min each time), fixed with 4% paraformaldehyde for 20 min at room temperature, washed with PBS another three times, permeated with 0.1% Triton X-100 in 0.1% sodium citrate for 2 min on ice, and washed with PBS a further three times. The cells were then incubated with 50 μL of TUNEL reaction solution.
mixture in a humidified atmosphere for 1 h at 37°C in the dark, rinsed three times with PBS, subjected to fluorescent counterstaining with DAPI for 10 min at room temperature, washed with PBS three times, and finally treated with an antifluorescence quenching sealing tablet. The ratio of TUNEL-positive cells to the total number of cells was determined under a light microscope (Leica DM 3000) and used to calculate the proportion of apoptotic.

2.12. Statistical Analysis. SPSS 22.0 statistical software (IBM Corporation, Armonk, NY, USA) was used to analyze the data. The measurement data are expressed as the means ± standard deviation. The data from different groups were compared using the independent-samples t-test and one-way ANOVA. Pairwise comparisons of homogeneous data were performed using the least significant difference (LSD) test. P < 0.05 indicated statistical significance for all analyses.

3. Results

3.1. Identification of Active Ingredients and Target Selection. A total of 295 active compounds were identified in the ten herbs contained in QKF. The 9 active compounds in Radix Rehmanniae were identified. Thirty-five active compounds were identified in Radix Paonieae Alba. Twenty-two active compounds were identified from Sophorae Flavescentis. Eighteen active compounds were identified in Cortex Moutan Radicis. Twenty-one active compounds were identified in Poria cocos. Twelve active compounds were identified in Herba Dendrobi Rhizoma. Fourteen active compounds were identified in Rhizoma Acori Tatarinowii. Thirty-two active compounds were identified in Rhizoma Anemarrhenae. A total of 116 active compounds were identified in Sophora Flavescentis. Thirty-five active compounds were identified in Péricarpium Citri Reticulatae (Supplementary Tables 1 and 2). A total of 7433 target proteins were identified in QKF. Topological analysis of the protein interaction network nodes revealed a total of 1368 target proteins when the duplicates were removed. We constructed an ingredient-target network (Supplementary Table 3) (Figure 1). For disease target identification, we identified the AD-related targets in the OMIM, GeneCards, PharmGKB, GAD, and KEGG databases. We retrieved 1689 target genes corresponding to disease targets and identified 1218 target genes by screening (Supplementary Table 4).

3.2. PPI Network Construction and Functional Enrichment Analysis of QKF. There is a certain degree of signaling transduction between different signal pathways and targets. Therefore, the mechanism of action between targets can be analyzed by determining the interactions between proteins. We used String 11.0 to determine the PPIs among the 1368 targets of QKF and the 1218 targets related to AD, which include 284 nodes and 4183 edges. According to the established screening rules, 66 targets were identified as key targets related to the QKF treatment of AD (Supplementary Table 5) (Figure 2(a)). GO enrichment analysis revealed 58 entries related to AD (Supplementary Tables 6, 7, and 8) (Figures 2(b)–2(d)). KEGG enrichment analysis identified 22 pathways (P < 0.01) (Supplementary Table 9) (Figure 2(e)). The results indicated that apoptosis may be the main way where QKF exerts its effects during the treatment of AD. Therefore, we designed an in vitro experiment to verify our hypothesis.

3.3. QKF Protected Hippocampal Neuron Morphology. The morphology and growth of rat hippocampal neurons were observed under Nikon inverted fluorescence microscope at 4 h and 1, 3, 5, and 7 days (Figure 3(a)). Hippocampal neurons were resuspended just after their inoculation. Four hours later, most of the cells were adherent and presented a rounded shape that was surrounded by a halo; a few cells also showed protrusions. At day 1, the neurons were completely adherent; grew well with protrusions of different lengths; and showed a spindle-like, triangular, or irregular morphology; however, no clear connections between neurons were established. After 3 days of culture, the number of cell protrusions was increased, the cells were obviously thickened and elongated in shape, and connections between neurons began to form. After 5 days of culture, the neurons were plump with a surrounding halo and had become more connected. After 7 days of culture, the cell body was enlarged and plump, there was an obvious halo around the cells, and the synapse had become longer and thicker. The neurons had moved closer to each other and began to form cell populations, and the cell protrusions had formed a dense nerve fiber network. We next examined the neuronal cell morphology in each group following different treatments using an immunofluorescence microscope to image microtubule-associated protein-2 (MAP-2), which was predominantly localized within cell bodies and dendrites. The neurons in the control group were plump and dense, and their cell protrusions formed a dense and elaborate nerve fiber network. The neurons in the group treated with Aβ25-35 alone showed a smaller cell body with thinner and more damaged dendrites than those in the control group and sometimes presented a fragmented or beaded appearance, and the number of connections between neurons was decreased. However, after treatment with donepezil or QKF, the cell body became plumper, the dendrites became thicker, and the junctions between cells were tighter. The 25 mg mL−1 QKF group showed an improved effect compared to that in the QKF groups at the other tested doses (Figure 3(b)).

3.4. QKF Alleviated Neuronal Apoptosis Induced by Aβ25-35. A TUNEL assay was performed to examine apoptosis in hippocampal neurons. TUNEL-positive cells in the selected visual field were counted by the positive cell counting method, and the final values are presented as the ratio of the number of TUNEL-positive cells to the number of total cells. As shown in Figures 4(a) and 4(b), the apoptotic rate of the hippocampal neurons in the model group was visibly increased compared with that in the control group (P < 0.01). In comparison with that in the model group, treatment with QKF and donepezil reduced the apoptotic rate (P < 0.05,
$P < 0.01$). The 25 mg mL$^{-1}$ QKF group showed a greater decrease than the other two QKF groups that were tested ($P < 0.01$).

The expression levels of apoptosis-related proteins in rat hippocampal neurons were measured by Western blot (WB) analysis (Figures 4(c), 4(d)). There were no evident differences in the total p38 MAPK or caspase-3 protein expression levels among the six groups ($P > 0.05$). WB analysis showed significantly lower Bcl-2 protein levels in the model group compared with those in the control group ($P < 0.01$). The Bcl-2 protein expression level in the QKF and donepezil groups was increased compared to that in the model group ($P < 0.01$). QKF at 25 mg mL$^{-1}$ increased the expression of Bcl-2 to the greatest extent among the three doses of QKF examined ($P < 0.05, P < 0.01$). The expression levels of p-p38 MAPK, cleaved caspase-3, and Bax were increased in the model group compared with those in the control, donepezil, and 25 mg mL$^{-1}$ QKF groups ($P < 0.01$). Compared with those in the model group, the expression levels of Bax were decreased in the 6.25 mg mL$^{-1}$ QKF and 12.5 mg mL$^{-1}$ QKF groups ($P < 0.01$), and the expression levels of p-p38 MAPK were decreased in the 6.25 mg mL$^{-1}$ QKF ($P < 0.05$) and 12.5 mg mL$^{-1}$ groups ($P < 0.01$). The 12.5 mg mL$^{-1}$ QKF group exhibited downregulated expression levels of cleaved caspase-3 ($P < 0.05$), while the 6.25 mg mL$^{-1}$ QKF group did not show an evident difference in the expression of cleaved caspase-3.
Figure 2: Network construction and enrichment analysis. (a) The blue circle represents the key target of Qingxin kaiqiao fang in the treatment of Alzheimer’s disease; the edge represents the interaction between the targets predicted by String database, and the thicker the line is, the higher the confidence level is. (b) Biological process in GO enrichment analysis. (c) Cellular component in GO enrichment analysis. (d) Molecular function in GO enrichment analysis. (e) KEGG pathway enrichment analysis. GO, gene ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes.
Figure 3: Qingxin kaiqiao fang reduces the damage of Aβ25-35 to cell morphology. (a) Morphology characteristic of hippocampal neuronal cells at different stages (4 h, 1 day, 3 days, 5 days, and 7 days, respectively) (original magnification, ×400). (b) Immunofluorescence images of microtubule-associated protein-2 (green) and nucleus (blue) (original magnification, ×200).
caspase-3 compared with the model group (P > 0.05). Moreover, the altered protein expression levels in both the 25 mg mL⁻¹ QKF and donepezil groups showed a consistent trend, and there were no clear differences in the effects between these two groups (P > 0.05).

3.5. **QKF Increased Cell Viability.** A CCK-8 assay was used to test hippocampal neuron viability. As shown in Figure 5, there was a sharp decline in hippocampal neuron viability after 24 h of treatment with Aβ25-35 alone compared with that in the control group (P < 0.01). In comparison with the
model group, the QKF and donepezil groups showed significantly elevated cellular viability \((P < 0.01)\). The 25 mg mL\(^{-1}\) QKF group showed an obviously improved effect compared to the QKF groups treated with the other tested doses \((P < 0.01)\), indicating the concentration-dependent neuroprotective effect of QKF.

3.6. Inhibiting or Activating p38 MAPK Affected the Hippocampal Neuron Morphology. The abovementioned results demonstrated that 25 mg mL\(^{-1}\) QKF showed the best effect in terms of preserving the morphology and inhibiting the apoptotic rate of hippocampal neuronal cells among the three doses of QKF assessed. Therefore, 25 mg mL\(^{-1}\) QKF was used for the subsequent experiments. In addition, p38 MAPK activity was inhibited by SB203580 and activated by U46619 to determine whether the antiapoptotic effect of QKF on neurons was mediated by p38 MAPK silencing. Neurons in the 25 mg mL\(^{-1}\) QKF + SB203580 group were plumper, their synapses were longer and thicker, and the nerve fiber network was much more elaborate and dense compared to that in the other two groups (Figure 6).

3.7. Inhibiting or Activating p38 MAPK Affected Hippocampal Neuronal Apoptosis. As shown in Figures 7(a) and 7(b), the 25 mg mL\(^{-1}\) QKF + SB203580 group showed a lower apoptotic rate than the 25 mg mL\(^{-1}\) QKF group \((P < 0.01)\), and the rate of hippocampal neuron apoptosis was higher in the 25 mg mL\(^{-1}\) QKF + U46619 group than that in the 25 mg mL\(^{-1}\) QKF group \((P < 0.05)\). The apoptotic rate in the SB203580-treated group was notably lower than that in the 25 mg mL\(^{-1}\) QKF + U46619 group.

WB analysis was employed to measure the extent of p38 MAPK phosphorylation and the protein expression levels of p38 MAPK, caspase-3, cleaved caspase-3, Bax, and Bcl-2 among the three groups. As shown in Figures 7(c) and 7(d), compared with the 25 mg mL\(^{-1}\) QKF group, the SB203580-treated group showed higher expression levels of Bcl-2 \((P < 0.01)\) and lower expression levels of p-p38 MAPK, cleaved caspase-3, and Bax \((P < 0.05, P < 0.01)\). The expression levels of p-p38 MAPK, Bax, and cleaved caspase-3 in the U46619-treated group were significantly higher than those in the 25 mg mL\(^{-1}\) QKF group \((P < 0.01)\), and the level of Bcl-2 was markedly lower than that in the 25 mg mL\(^{-1}\) QKF group \((P < 0.01)\). There was no evident difference in the levels of p38 MAPK and caspase-3 \((P > 0.05)\) in the 25 mg mL\(^{-1}\) QKF + SB203580 or 25 mg mL\(^{-1}\) QKF + U46619 groups compared with the H-QKF group. These results demonstrated that inhibiting p38 MAPK blocked apoptosis, while p38 MAPK activation produced an inverse effect compared to that of p38 MAPK pathway inhibition.

3.8. Inhibiting or Activating p38 MAPK Affected Cell Viability. The cell survival rate was calculated as \((\text{OD experimental group - OD blank group}) / (\text{OD 25 mg/mL QKF group - OD blank group}) \times 100\%\). In comparison with that in the 25 mg mL\(^{-1}\) QKF group, hippocampal neuron viability in the 25 mg mL\(^{-1}\) QKF + SB203580 group was obviously increased \((P < 0.01)\), and cell viability in the 25 mg mL\(^{-1}\) QKF + U46619 group was notably decreased \((P < 0.01)\) (Figure 8). These findings indicated that inhibiting p38 MAPK activity elevates hippocampal neuron viability and that activating the p38 MAPK pathway inhibits hippocampal neuron viability.

4. Discussion

\(A\beta_{25-35}\), a short fragment of the \(A\beta\) peptide that is related to AD, has been found in experimental studies to have amyloidogenic, aggregative, and neurotoxic features. \(A\beta_{25-35}\) sedimented faster, indicating an increased tendency toward aggregation compared with \(A\beta_{1-42}\), which is another peptide widely used to develop AD models in vivo and in vitro and to generate apoptotic signals leading to cell death [14, 15]. Neuronal apoptosis, which is an important cell process and the main mechanism of neuronal death, plays an essential role in neurodegeneration in AD. The
The significance of apoptosis in the pathogenesis of AD has attracted increasing attention [16]. In a normal physiological environment, apoptosis and the natural antiapoptotic defense system exist in a dynamic balance and the excessive accumulation and deposition of Aβ disrupt this balance [17]. The present study revealed that Aβ25-35 at 10 μmol·L−1 destroyed cell morphology, disrupted the connections between neurons, decreased cell viability, and increased the number of TUNEL-positive cells. However, these effects were improved after treatment with QKF, which has been used to treat AD for many years and has shown remarkable effects on early symptoms such as cognitive dysfunction and behavioral symptoms [18].

Network pharmacology prediction was applied to deeply explore the potential mechanisms underlying the effects of QKF on AD. We first screened the active compounds of QKF and identified the target proteins of QKF. Then, the QKF-compound-target-AD network was constructed, and enrichment analysis was performed. Our analysis indicated that QKF was mainly targeted in the cell cycle, cell proliferation, apoptosis, and inflammation in the treatment of AD. It can be seen from the above enrichment analysis that both the MAPK pathway and the apoptotic process are very important. In our previous in vivo study, QKF was found to successfully ameliorate memory impairment and inhibit apoptosis in APP/PS1 double transgenic mice through its effects on the p38 MAPK pathway [19]. Mammalian p38 MAPK, a member of the MAPK family, is mainly involved in promoting apoptosis. Aβ aggregated as extracellular plaques phosphorylates p38 MAPK, which then induces tau hyperphosphorylation, reduces synaptic plasticity, and eventually induces neuronal apoptosis [20]. The results of the WB analysis in our present in vitro study showed that the phosphorylation of p38 MAPK was significantly increased in the model group compared with the control group. In the QKF-treated group, a significant decrease in the protein expression of p-p38 MAPK was observed compared with the model group. In addition to the role of p38 MAPK in apoptosis, a family of intracellular cysteine proteases known as caspases are known to exhibit apoptotic effects and to be involved in the intrinsic mitochondrial apoptosis pathway [21]. Caspase-3, the final executor of apoptosis and the best-characterized apoptosis executor within the caspase family, can be cleaved by an activated upstream caspase [22]. Following the exposure of cells to apoptotic stimuli, caspase activation has been demonstrated to rely on the presence of cytochrome c released from mitochondria; however, apoptosis can be prevented by the presence of Bcl-2 in these organelles [23]. Bcl-2 is an integral membrane protein
located mainly on the outer membrane of mitochondria that are known for improving cell survival and preventing cells from undergoing apoptosis [24]. In contrast, the related protein Bax facilitates apoptosis and counters the anti-apoptotic role of Bcl-2 (the potential mechanism is shown in Figure 9). The results of the WB analysis in the present study showed that QKF, especially at a dose of 25 mg mL\(^{-1}\), rescued hippocampal neurons from A\(_\beta\)-induced apoptosis by reducing the expression of Bax and cleaved caspase-3 and by enhancing the expression of Bcl-2.

Because p38 MAPK plays a role in the process of apoptosis, the p38 MAPK inhibitor SB203580 has been used to decrease p38 MAPK activation by many researchers [25, 26]. In this study, to verify that the inhibition of p38 MAPK activity has an antiapoptotic effect, U46619, an agonist of p38 MAPK, was applied [27, 28]. Our results demonstrated that the 25 mg mL\(^{-1}\) QKF + SB203580 group, but not the U46619-treated group, exhibited increased preservation of neuronal morphology, enhanced neuron viability, a decreased number of TUNEL-positive cells, upregulated expression of an antiapoptotic protein, and downregulated expression of proapoptotic proteins. These findings suggest that QKF prevents apoptosis in AD by silencing the p38 MAPK pathway.

**Figure 7:** 25 mg mL\(^{-1}\) QKF alleviates neuronal apoptosis by p38 MAPK silencing. (a) TUNEL staining in each group of hippocampal neurons (original magnification, \(\times 200\)). (b) Statistical analysis results of TUNEL staining. (c) The gray value of associated proteins in each group. (d) Relative protein expression in each group, as detected by WB analysis. Data are expressed as mean \(\pm\) SD (\(n = 5\)); significant differences between the two groups are indicated as \(* P < 0.05\) and \(** P < 0.01\). QKF, Qingxin kaiqiao fang.
5. Conclusion

QKF, especially the high-dose group of 25 mg mL⁻¹, may inhibit Aβ25-35-induced hippocampal neuron apoptosis by blocking the p38 MAPK pathway. Moreover, our finding also demonstrated that network pharmacology was a reliable way to find targets and possible mechanisms of traditional Chinese medicine.

Data Availability

The basic studying data used to support the findings of this study were supplied by Dr. Tian-Qi Wang under license and so cannot be made freely available. Requests for access to these data should be made to Dr. Tian-Qi Wang, tenkiou@foxmail.com.
Conflicts of Interest

The authors declare that there are no conflicts of interest.

Authors’ Contributions

Tian-Qi Wang wrote the manuscript text. Tian-Qi Wang, Xiao-Xiao Lai, Lu-Ting Xu, and Yan Shen prepared figures and collected samples. Jian-Wei Lin and Shi-Yu Gao analyzed data. Hai-Yan Hu and Tian-Qi Wang designed the experiment. All authors contributed toward data analysis and drafting and critically revising the paper; gave final approval of the version to be published; and agree to be accountable for all aspects of the work.

Acknowledgments

This work was supported by the Second Affiliated Hospital and Yuying Children’s Hospital of Wenzhou Medical University Scientific Research Center, the National Natural Science Foundation of China (grant no. 81573896), and the Natural Science Foundation of Zhejiang Province (grant no. LY15H270016).

Supplementary Materials

The data of active ingredients and targets are listed in Supplementary Materials. The data of PPI Network and Functional Enrichment Analysis can be seen in Supplementary Tables 5, 6, 7, 8, and 9. (Supplementary Materials)

References

[1] F. Xiao, S. Gao, Q. Yi, and P. Yu, “TGF-β1 protection against Aβ1-42-induced hippocampal neuronal inflammation and apoptosis by TLR-1,” NeuroReport, vol. 29, no. 2, pp. 141–146, 2018.

[2] S. Shimohama, “Apolisosis in Alzheimer’s disease--an update,” Apoptosis: An International Journal on Programmed Cell Death, vol. 5, no. 1, pp. 9–16, 2000.

[3] S. Ami and K. Dimitri, “Binding of cytotoxic a β 25-35 peptide to the dimyristoylphosphatidylcholine lipid bilayer,” Journal of Chemical Information and Modeling, vol. 58, no. 5, pp. 1053–1065, 2018.

[4] F. Sengnou, Z. Bei, L. Ping et al., “PI3K/AKT/mTOR/p70S6K pathway is involved in Aβ25-35-induced autophagy,” BioMed Research International, vol. 2015, Article ID 161020, 19 pages, 2015.

[5] L. Stephanie, L. Susan, B. Rachal, and J. William, “Hippocampal activation is associated with longitudinal amyloid accumulation and cognitive decline,” eLife, vol. 6, 2017.

[6] X. Yan, C. Da, W. Gui, and H. Xiao, “Involvement of P38MAPK activation by NMDA receptors and non-NMDA receptors in amyloid-β peptide-induced neuronal loss in rat hippocampal CA1 and CA3 subfields,” Neuroscience Research, vol. 85, pp. 51–57, 2014.

[7] T. Wipawan, P. Nicha, C. Vorapin et al., “N-benzylcinnamamide protects rat cultured cortical neurons from β-amyloid peptide-induced neurotoxicity,” Neuroscience Letters, vol. 556, pp. 20–25, 2013.

[8] L. Jong and K. Nam, “Recent advances in the inhibition of p38 MAPK as a potential strategy for the treatment of Alzheimer’s disease,” Molecules (Basel, Switzerland), vol. 22, no. 8, 2017.

[9] G. Xiao, C. Yu, and Z. Li, “p38 mitogen-activated protein kinase gene silencing rescues rat hippocampal neurons from ketamine-induced apoptosis: an in vitro study,” International Journal of Molecular Medicine, vol. 42, no. 3, pp. 1401–1410, 2018.

[10] N. Hironori, M. Ryuichi, Y. Kei et al., “Phosphorylation of p38 mitogen-activated protein kinase downstream of bax-caspase-3 pathway leads to cell death induced by high D-glucose in human endothelial cells,” Diabetics, vol. 50, no. 6, pp. 1472–1481, 2001.

[11] Z. Zong, X. Bao, L. Song, Y. Tian, and P. Sun, “Role of miR-106-mediated mitogen-activated protein kinase signaling pathway in oxidative stress injury and inflammatory infiltration in the liver of the mouse with gestational hypertension,” Journal of Cellular Biochemistry, 2019.

[12] R. Hiaidou, M. Qinghe, and Y. Nateh, “Protective effects of glutathione on oxidative injury induced by hydrogen peroxide in intestinal epithelial cells,” The Journal of Surgical Research, vol. 222, pp. 39–47, 2018.

[13] B. Dadio, S. Zhuo, Z. Junbo, M. Mei, and W. Changl, “Study of the mechanism underlying therapeutic effect of Compound Longmaining on myocardial infarction using a network pharmacology-based approach,” Biomedical & Pharmacotherapy, vol. 118, Article ID 109234, 2019.

[14] M. Elisabetta, S. Marin, M. Coletta, F. O. S. B. G. K., and F. Misi, “Abeta(31-35) and Abeta(25-35) fragments of amyloid beta-protein induce cellular death through apoptotic signals: role of the redox state of methionine-35,” FEBS Letters, vol. 579, no. 13, pp. 2913–2918, 2005.

[15] C. Pike, D. Burdick, A. Walencewicz, C. Glabe, and C. Cotman, “Neurodegeneration induced by beta-amyloid peptides in vitro: the role of peptide assembly state,” The Journal of Neuroscience: The Official Journal of the Society for Neuroscience, vol. 13, no. 4, pp. 1676–1687, 1993.

[16] D. Telekina, K. Suvorov, S. Kozhevnikova, and G. Kolosova, “Mechanisms of neuronal death in the cerebral Cortex during aging and development of Alzheimer’s disease-like pathology in rats,” International Journal of Molecular Sciences, vol. 20, no. 22, 2019.

[17] H. Sui, L. Zhang, Z. Liu, and Y. Jin, “Atorvastatin prevents Aβ oligomer-induced neurotoxicity in cultured rat hippocampal neurons by inhibiting Tau cleavage,” Acta Pharmacologica Sinica, vol. 36, no. 5, pp. 553–564, 2015.

[18] H. Hai, C. Zhi, L. Hui et al., “Fumanjian, a classic Chinese herbal formula, can ameliorate the impairment of spatial learning and memory through apoptotic signaling pathway in the hippocampus of rats with Aβ 1-40 -induced alzheimer’s disease,” Evidence-Based Complementary and Alternative Medicine, vol. 2014, Article ID 942917, 9 pages, 2014.

[19] L. Xu, X. Lai, Y. Shen, J. Lin, S. Gao, H. Hu et al., “Qingxin kaqiao fang ameliorates memory impairment and inhibits apoptosis in APP/PS1 double transgenic mice through the MAPK pathway,” Drug Design, Development and Therapy, vol. 13, pp. 459–475, 2019.

[20] G. Kheiri, M. Dolatshahi, F. Rahmani, and N. Rezaei, “Role of p38/MEKs in Alzheimer’s disease: implications for amyloid beta toxicity targeted therapy,” Reviews in the Neurosciences, vol. 30, no. 1, pp. 9–30, 2018.

[21] O. Brustugun, K. Fladmark, S. Doskeland, S. Orrenius, and B. Zhivotovsky, “Apoptosis induced by microinjection of...
cytochrome c is caspase-dependent and is inhibited by Bcl-2,”
Cell Death and Differentiation, vol. 5, no. 8, pp. 660–668, 1998.

[22] W. Shu, N. Lean, and L. Chun, “Effects of antioxidants and
caspase-3 inhibitor on the phenylethyl isothiocyanate-in-
duced apoptotic signaling pathways in human PLC/PRF/5
cells,” European Journal of Pharmacology, vol. 518, pp. 96–106,
2005.

[23] J. Yang. “Prevention of apoptosis by Bcl-2: release of cyto-
chrome c from mitochondria blocked,” Science, vol. 275,
no. 5303, pp. 1129–1132, 1997.

[24] K. Kuan, L. Shing, L. Wei et al., “The deubiquitinating enzyme
inhibitor PR-619 enhances the cytotoxicity of cisplatin via the
suppression of anti-apoptotic bcl-2 protein: in vitro and in
vivo study,” Cells, vol. 8, no. 10, 2019.

[25] S. Jantira, P. Eakkapote, A. Punyanuch et al., “Combination of
metformin and p38 MAPK inhibitor, SB203580, reduced
myocardial ischemia/reperfusion injury in non-obese type 2
diabetic Goto-Kakizaki rats,” Experimental and Therapeutic
Medicine, vol. 18, no. 3, pp. 1701–1714, 2019.

[26] W. Ya, Z. Tianming, D. You et al., “Genipin ameliorates
carbon tetrachloride-induced liver injury in mice via the
concomitant inhibition of inflammation and induction of
autophagy,” Oxidative medicine and cellular longevity,
vol. 2019, Article ID 3729051, 12 pages, 2019.

[27] S. Liping, K. Xiaocen, L. Szyun et al., “The prostaglandin H2
analog U-46619 improves the differentiation efficiency of
human induced pluripotent stem cells into endothelial cells by
activating both p38MAPK and ERK1/2 signaling pathways,”
Stem Cell Research & Therapy, vol. 9, no. 1, p. 313, 2018.

[28] R. Zhou, X. Yang, X. Li et al., “Recombinant CC16 inhibits
NLRP3/caspase-1-induced pyroptosis through p38 MAPK
and ERK signaling pathways in the brain of a neonatal rat
model with sepsis,” Journal of Neuroinflammation, vol. 16,
no. 1, p. 239, 2019.